Screener / SEC EDGAR /CIK 0001178670 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Alnylam Pharmaceuticals, Inc. ALNY

Compare with peers Embed
Planned sales, announced before they happen

1 trading plan running, 11 Form 144 notices for $12.9M

10-Q, 10-K and Form 144

What ALNY's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Sep 12, 2024 to Aug 6, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Tolga Tanguler
Chief Commercialization Officer
Adopted 10b5-1 plan Aug 24, 2026 10-Q Oct 29, 2026
What the company wrote
Tolga Tanguler, Chief Commercialization Officer On August 24, 2026, Tolga Tanguler, our Chief Commercialization Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 22,438 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from November 23, 2026 to August 6, 2027. The plan is scheduled to terminate on August 6, 2027, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan.
Pushkal Garg, M.D
Chief Research and Development Officer
Adopted 10b5-1 plan Nov 20, 2025 10-K Feb 12, 2026
What the company wrote
Pushkal Garg, M.D., Chief Research and Development Officer On November 20, 2025, Pushkal Garg, M.D. our Chief Research and Development Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Garg, acting through a broker, may sell up to an aggregate of 25,418 shares of our common stock received upon the settlement of awards granted to Dr. Garg as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from February 27, 2026 to November 1, 2026. The plan is scheduled to terminate on November 1, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Garg or the broker, or as otherwise provided in the plan.
Tolga Tanguler
Chief Commercial Officer
Adopted 10b5-1 plan Nov 14, 2025 10-K Feb 12, 2026
What the company wrote
Tolga Tanguler, Chief Commercial Officer On November 14, 2025, Tolga Tanguler, our Chief Commercial Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 25,782 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from February 13, 2026 to November 15, 2026. The plan is scheduled to terminate on November 15, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan.
Kevin J. Fitzgerald, Ph.D
Chief Scientific Officer
Adopted 10b5-1 plan Aug 14, 2025 10-Q Oct 30, 2025
What the company wrote
Kevin J. Fitzgerald, Ph.D., Chief Scientific Officer On August 14, 2025, Kevin J. Fitzgerald, Ph.D., our Chief Scientific Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Fitzgerald, acting through a broker, may sell up to an aggregate of 30,013 shares of our common stock received upon the settlement of awards granted to Dr. Fitzgerald as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from November 12, 2025 to August 15, 2026. The plan is scheduled to terminate on August 15, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Fitzgerald or the broker, or as otherwise provided in the plan.
Yvonne L. Greenstreet, M.D
Chief Executive Officer and Director
Adopted 10b5-1 plan Aug 13, 2025 10-Q Oct 30, 2025
What the company wrote
Yvonne L. Greenstreet, M.D., Chief Executive Officer and Director On August 13, 2025, Yvonne L. Greenstreet, M.D., our Chief Executive Officer and a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Dr. Greenstreet, acting through a broker, may sell up to an aggregate of 25,650 shares of our common stock received upon the settlement of awards granted to Dr. Greenstreet as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from November 11, 2025 to May 14, 2026. The plan is scheduled to terminate on May 14, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Greenstreet or the broker, or as otherwise provided in the plan.
Colleen F. Reitan
Director
Adopted 10b5-1 plan Jun 10, 2025 10-Q Jul 31, 2025
What the company wrote
Colleen F. Reitan, Director On June 10, 2025, Colleen F. Reitan, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Ms. Reitan, acting through a broker, may sell up to an aggregate of 18,000 shares of our common stock received upon the exercise of options granted to Ms. Reitan as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from September 9, 2025 to May 15, 2026. The plan is scheduled to terminate on May 15, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Ms. Reitan or the broker, or as otherwise provided in the plan.
Tolga Tanguler
Chief Commercial Officer
Adopted 10b5-1 plan May 27, 2025 10-Q Jul 31, 2025
What the company wrote
Tolga Tanguler, Chief Commercial Officer On May 27, 2025, Tolga Tanguler, our Chief Commercial Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 3,474 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from August 29, 2025 to May 10, 2026. The plan is scheduled to terminate on May 10, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan.
Dennis A. Ausiello, M.D.
Director
Adopted 10b5-1 plan May 15, 2025 10-Q Jul 31, 2025
What the company wrote
Dennis A. Ausiello, M.D., Director On May 15, 2025, Dennis A. Ausiello, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Dr. Ausiello, acting through a broker, may sell up to an aggregate of 31,448 shares of our common stock received upon the exercise of options granted to Dr. Ausiello as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from August 13, 2025 to May 1, 2026. The plan is scheduled to terminate on May 1, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Ausiello or the broker, or as otherwise provided in the plan.
Michael W. Bonney
Director
Adopted 10b5-1 plan Nov 12, 2024 10-K Feb 13, 2025
What the company wrote
Michael W. Bonney, Director On November 12, 2024, Michael W. Bonney, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Bonney, acting through a broker, may sell up to an aggregate of 22,500 shares of our common stock received upon the exercise of options granted to Mr. Bonney as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from February 12, 2025 to June 3, 2026. The plan is scheduled to terminate on June 3, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Bonney or the broker, or as otherwise provided in the plan
Tolga Tanguler
Chief Commercial Officer
Adopted 10b5-1 plan Sep 12, 2024 10-Q Oct 31, 2024
What the company wrote
Tolga Tanguler, Chief Commercial Officer On September 12, 2024, Tolga Tanguler, our Chief Commercial Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 4,070 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from December 13, 2024 to May 10, 2025. The plan is scheduled to terminate on May 10, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan.
Yvonne L. Greenstreet
Chief Executive Officer and Director
Adopted 10b5-1 plan Sep 12, 2024 10-Q Oct 31, 2024
What the company wrote
Yvonne L. Greenstreet, MBChB, MBA, Chief Executive Officer and Director On September 12, 2024, Yvonne L. Greenstreet, MBChB, MBA, our Chief Executive Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Greenstreet, acting through a broker, may sell up to an aggregate of 50,937 shares of our common stock received upon the settlement of awards granted to Dr. Greenstreet as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from December 16, 2024 to June 6, 2025. The plan is scheduled to terminate on June 6, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Greenstreet or the broker, or as otherwise provided in the plan.
Pushkal P. Garg
Chief Medical Officer
Adopted 10b5-1 plan Sep 11, 2024 10-Q Oct 31, 2024
What the company wrote
Pushkal P. Garg, Chief Medical Officer On September 11, 2024, Pushkal P. Garg, our Chief Medical Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Garg, acting through a broker, may sell up to an aggregate of 94,925 shares of our common stock received upon the settlement of awards granted to Dr. Garg as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from December 12, 2024 to December 18, 2025. The plan is scheduled to terminate on December 18, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Garg or the broker, or as otherwise provided in the plan.
David E.I. Pyott
Director
Adopted 10b5-1 plan Sep 5, 2024 10-Q Oct 31, 2024
What the company wrote
David E.I. Pyott, Director On September 5, 2024, David E.I. Pyott, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Pyott, acting through a broker, may sell up to an aggregate of 7,440 shares of our common stock received upon the exercise of options granted to Mr. Pyott as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from January 1, 2025 to December 17, 2025. The plan is scheduled to terminate on December 17, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Pyott or the broker, or as otherwise provided in the plan.
Kevin Fitzgerald
Executive Vice President, Chief Scientific Officer
Adopted 10b5-1 plan May 10, 2024 10-Q Aug 1, 2024
What the company wrote
Kevin Fitzgerald, Ph.D., Executive Vice President, Chief Scientific Officer On May 10, 2024, Kevin Fitzgerald, Ph.D., our Executive Vice President, Chief Scientific Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Fitzgerald, acting through a broker, may sell up to an aggregate of 50,634 shares of our common stock received upon the settlement of awards granted to Dr. Fitzgerald as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from August 11, 2024 to May 10, 2025. The plan is scheduled to terminate on May 10, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Fitzgerald or the broker, or as otherwise provided in the plan.
Dennis A. Ausiello
Director
Adopted 10b5-1 plan May 3, 2024 10-Q Aug 1, 2024
What the company wrote
Dennis A. Ausiello, M.D., Director On May 3, 2024, Dennis A. Ausiello, M.D., a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Dr. Ausiello, acting through a broker, may sell up to an aggregate of 20,250 shares of our common stock received upon the exercise of options granted to Dr. Ausiello as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from August 5, 2024 to May 20, 2025. The plan is scheduled to terminate on May 20, 2025, subject to earlier termination upon the sale of all shares subject to the plan upon termination by Dr. Ausiello or the broker, or as otherwise provided in the plan.
Yvonne L. Greenstreet
Chief Executive Officer and Director
Adopted 10b5-1 plan Mar 12, 2024 10-Q May 2, 2024
What the company wrote
Yvonne L. Greenstreet, MBChB, MBA, Chief Executive Officer and Director On March 12, 2024, Yvonne L. Greenstreet, MBChB, MBA, our Chief Executive Officer, entered into a Rule 10b5-1 trading plan that provides that Dr. Greenstreet, acting through a broker, may sell up to an aggregate of 37,241 shares of our common stock received upon the settlement of awards granted to Dr. Greenstreet as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from June 19, 2024 to March 7, 2025. The plan is scheduled to terminate on March 7, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Dr. Greenstreet or the broker, or as otherwise provided in the plan.
Amy W. Schulman
Director
Adopted 10b5-1 plan Feb 28, 2024 10-Q May 2, 2024
What the company wrote
Amy W. Schulman, Director On February 28, 2024, Amy W. Schulman, Chair of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Ms. Schulman, acting through a broker, may sell up to an aggregate of 30,200 shares of our common stock received upon the exercise of options granted to Ms. Schulman as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from May 29, 2024 to November 15, 2024. The plan is scheduled to terminate on November 15, 2024, subject to earlier termination upon the sale of all shares subject to the plan upon termination by Ms. Schulman or the broker, or as otherwise provided in the plan.
David E.I. Pyott
Director
Adopted 10b5-1 plan Aug 11, 2023 10-Q Nov 2, 2023
What the company wrote
On August 11, 2023, David E.I. Pyott, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Pyott, acting through a broker, may sell up to an aggregate of 32,450 shares of our common stock received upon the exercise of options granted to Mr. Pyott as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from November 16, 2023 to November 15, 2024. The plan is scheduled to terminate on November 15, 2024, subject to earlier termination upon the sale of all shares subject to the plan upon termination by Mr. Pyott or the broker, or as otherwise provided in the plan.
Michael W. Bonney
Director
Adopted 10b5-1 plan Aug 10, 2023 10-Q Nov 2, 2023
What the company wrote
On August 10, 2023, Michael W. Bonney, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Bonney, acting through a broker, may sell up to an aggregate of 30,000 shares of our common stock received upon the exercise of options granted to Mr. Bonney as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from November 13, 2023 to December 17, 2024. The plan is scheduled to terminate on December 17, 2024, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Bonney or the broker, or as otherwise provided in the plan.
Tolga Tanguler
Chief Commercial Officer
Adopted 10b5-1 plan May 18, 2023 10-Q Aug 3, 2023
What the company wrote
On May 18, 2023, Tolga Tanguler, our Chief Commercial Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Tanguler, acting through a broker, may sell up to an aggregate of 20,024 shares of our common stock received upon the settlement of awards granted to Mr. Tanguler as equity incentive compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from August 16, 2023 to May 10, 2024. The plan is scheduled to terminate on May 10, 2024, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Tanguler or the broker, or as otherwise provided in the plan.
Phillip A. Sharp
member of our board of directors
Adopted 10b5-1 plan May 16, 2023 10-Q Aug 3, 2023
What the company wrote
On May 16, 2023, Phillip A. Sharp, Ph.D., a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Dr. Sharp, acting through a broker, may sell up to an aggregate of 63,750 shares of our common stock received upon the exercise of options granted to Dr. Sharp as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from September 1, 2023 to June 3, 2024. The plan is scheduled to terminate on June 3, 2024, subject to earlier termination upon the sale of all shares subject to the plan upon termination by Dr. Sharp or the broker, or as otherwise provided in the plan.
David E.I. Pyott
member of our board of directors
Adopted 10b5-1 plan – 10-K Feb 12, 2026
What the company wrote
David E.I. Pyott, Director On November 12, 2025, David E.I. Pyott, a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Pyott, acting through a broker, may sell up to an aggregate of 7,610 shares of our common stock received upon the exercise of options granted to Mr. Pyott as director compensation, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur if the market price of our common stock is above specified prices from February 11, 2026 to October 14, 2026. The plan is scheduled to terminate on October 14, 2026, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Pyott or the broker, or as otherwise provided in the plan
Show the other 14 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 4, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Oct 2, 2026 SUPRAN BRYAN
Officer
1,758 $399K
Jun 1, 2026 PYOTT DAVID E I
Director
3,830 $1.1M
Apr 6, 2026 McLaughlin Melissa
Officer
2,286 $732K
Mar 5, 2026 Fitzgerald Kevin Joseph
Officer
658 $213K
Mar 5, 2026 Garg Pushkal
Officer
2,404 $778K
Mar 3, 2026 Fitzgerald Kevin Joseph
Officer
1,652 $531K
Mar 3, 2026 Garg Pushkal
Officer
1,775 $570K
Feb 27, 2026 Garg Pushkal
Officer
4,627 $1.5M
Feb 17, 2026 Fitzgerald Kevin Joseph
Officer
2,041 $678K
Jan 13, 2026 Fitzgerald Kevin Joseph
Officer
2,290 $845K
Nov 17, 2025 Fitzgerald Kevin Joseph
Officer
12,128 $5.4M
Show the other 3 notices

From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALNY/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.